Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a 'mixed matrix

Nanomedicine

Volumn 9, Issue 16, 2014, Pages 2467-2479

  Liptrott, Neill J ^a   Kendall, Emily ^a   Nieves, Daniel J ^a   Farrell, John ^a   Rannard, Steve ^a   Fernig, David G ^a   Owen, Andrew ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

gold nanoparticle; immune cells; immune interaction; ligand shell

Indexed keywords

GAMMA INTERFERON; GOLD NANOPARTICLE; INTERLEUKIN 10; PHYTOHEMAGGLUTININ; GOLD; METAL NANOPARTICLE;

ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOKINE RELEASE; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNE SYSTEM; LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; SURFACE PROPERTY; SYNTHESIS; T LYMPHOCYTE ACTIVATION; BIOSYNTHESIS; CHEMISTRY; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MONONUCLEAR CELL;

CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; GOLD; HUMANS; IMMUNE SYSTEM; INTERFERON-GAMMA; INTERLEUKIN-10; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; METAL NANOPARTICLES; SURFACE PROPERTIES;

EID: 84918536669     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.38     Document Type: Article

References (67)

1. Dykman L, Khlebtsov N. Gold nanoparticles in biomedical applications: recent advances and perspectives. Chem. Soc. Rev. 41(6), 2256-2282 (2012).
2. Dreaden EC, Alkilany AM, Huang X, Murphy CJ, El-Sayed MA. The golden age: gold nanoparticles for biomedicine. Chem. Soc. Rev. 41(7), 2740-2779 (2012).
3. Yeh YC, Creran B, Rotello VM. Gold nanoparticles: preparation, properties, and applications in bionano-technology. Nanoscale 4(6), 1871-1880 (2012).
4. De Barros AB, Tsourkas A, Saboury B, Cardoso VN, Alavi A. Emerging role of radiolabeled nanoparticles as an effective diagnostic technique. EJNMMI Res. 2(1), 39 (2012).
5. Chen G, Ohulchanskyy TY, Liu S et al. Core/shell NaGdF4: Nd(3+)/NaGdF4 nanocrystals with effcient near-infrared to near-infrared downconversion photoluminescence for bioimaging applications. ACS Nano 6(4), 2969-2977 (2012).
6. Kumar A, Ma H, Zhang X et al. Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment. Biomaterials 33(4), 1180-1189 (2012).
7. Duchesne L, Gentili D, Comes-Franchini M, Fernig DG. Robust ligand shells for biological applications of gold nanoparticles. Langmuir 24(23), 13572-13580 (2008).
8. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 5(4), 487-495 (2008).
9. Dobrovolskaia MA, Clogston JD, Neun BW, Hall JB, Patri AK, McNeil SE. Method for analysis of nanoparticle hemolytic properties in vitro. Nano Lett. 8(8), 2180-2187 (2008).
10. Dobrovolskaia MA, Germolec DR, Weaver JL. Evaluation of nanoparticle immunotoxicity. Nat. Nanotechnol. 4(7), 411-414 (2009).
11. Dobrovolskaia MA, McNeil SE. Understanding the correlation between in vitro and in vivo immuno-toxicity tests for nanomedicines. J. Control. Release 172(2), 456-466 (2013).
12. Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat. Nanotechnol. 2(8), 469-478 (2007).
13. Thakor AS, Jokerst J, Zavaleta C, Massoud TF, Gambhir SS. Gold nanoparticles: a revival in precious metal administration to patients. Nano Lett. 11(10), 4029-4036 (2011).
14. Mcmahon SJ, Hyland WB, Muir MF et al. Biological consequences of nanoscale energy deposition near irradiated heavy atom nanoparticles. Sci. Rep. 1, 18 (2011).
15. Goy-Lopez S, Juarez J, Alatorre-Meda M et al. Physicochemical characteristics of protein-NP bioconjugates: the role of particle curvature and solution conditions on human serum albumin conformation and fbrillogenesis inhibition. Langmuir 28(24), 9113-9126 (2012).
16. Lartigue L, Wilhelm C, Servais J et al. Nanomagnetic sensing of blood plasma protein interactions with iron oxide nanoparticles: impact on macrophage uptake. ACS Nano 6(3), 2665-2678 (2012).
17. Elbakry A, Wurster EC, Zaky A et al. Layer-by-layer coated gold nanoparticles: size-dependent delivery of DNA into cells. Small 8(24), 3847-3856 (2012).
18. Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl Acad. Sci. USA 105(38), 14265-14270 (2008).
19. Hulander M, Lundgren A, Berglin M, Ohrlander M, Lausmaa J, Elwing H. Immune complement activation is attenuated by surface nanotopography. Int. J. Nanomedicine 6, 2653-2666 (2011).
20. Deng ZJ, Liang M, Monteiro M, Toth I, Minchin RF. Nanoparticle-induced unfolding of fbrinogen promotes Mac-1 receptor activation and infammation. Nat. Nanotechnol. 6(1), 39-44 (2011).
21. Deng ZJ, Liang MT, Toth I, Monteiro M, Minchin RF. Plasma protein binding of positively and negatively charged polymer-coated gold nanoparticles elicits different biological responses. Nanotoxicology 7(3), 314-322 (2013).
22. Deng ZJ, Liang MT, Toth I, Monteiro MJ, Minchin RF. Molecular interaction of poly(acrylic acid) gold nanoparticles with human fbrinogen. ACS Nano 6(10), 8962-8969 (2012).
23. Chen XY, Qoutah W W, Free P, Hobley J, Fernig DG, Paramelle D. Features of thiolated ligands promoting resistance to ligand exchange in self-assembled monolayers on gold nanoparticles. Aust. J. Chem. 65, 266-274 (2012).
24. Duchesne L, Octeau V, Bearon RN et al. Transport of fbroblast growth factor 2 in the pericellular matrix is controlled by the spatial distribution of its binding sites in heparan sulfate. PloS Biol. 10, e1001361 (2012).
25. Lutsiak ME, Kwon GS, Samuel J. Biodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses. J. Pharm. Pharmacol. 58(6), 739-747 (2006).
26. Diwan M, Elamanchili P, Cao M, Samuel J. Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle deliver y. Curr. Drug Deliv. 1(4), 405-412 (2004).
27. Chong CS, Cao M, Wong WW et al. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J. Control. Release 102(1), 85-99 (2005).
28. Van Zijverden M, Granum B. Adjuvant activity of particulate pollutants in different mouse models. Toxicology 152 (1-3), 69-77 (2000).
29. De Kozak Y, Andrieux K, Villarroya H et al. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur. J. Immunol. 34(12), 3702-3712 (2004).
30. Haiss W, Thanh NTK, Aveyard J, Fernig DG. Determination of size and concentration of gold nanoparticles from UV-Vis spectra. Anal. Chem. 79, 4215-4221 (2007).
31. + T cells and monocyte-derived macrophages restrict their intracellular accumulation. J. Antimicrob. Chemother. 68(11) 2545-2549 (2013).
32. Farrell J, Jenkinson C, Lavergne SN, Maggs JL, Kevin Park B, Naisbitt DJ. Investigation of the immunogenicity of p-phenylenediamine and Bandrowski's base in the mouse. Toxicol. Lett. 185 (3), 153-159 (2009).
33. Owens DE, 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307(1), 93-102 (2006).
34. Casals E, Pfaller T, Duschl A, Oostingh GJ, Puntes V. Time evolution of the nanoparticle protein corona. ACS Nano 4(7), 3623-3632 (2010).
35. Prach M, Stone V, Proudfoot L. Zinc oxide nanoparticles and monocytes: impact of size, charge and solubility on activation status. Toxicol. Appl. Pharmacol. 266(1), 19-26 (2013).
36. Plascencia-Villa G, Starr CR, Armstrong LS, Ponce A, Jose-Yacaman M. Imaging interactions of metal oxide nanoparticles with macrophage cells by ultra-high resolution scanning electron microscopy techniques. Integr. Biol. (Camb.) 4(11), 1358-1366 (2012).
37. Sapozhnikova V, Willsey B, Asmis R et al. Use of near-infrared luminescent gold nanoclusters for detection of macrophages. J. Biomed. Opt. 17(2), 026006 (2012).
38. Larson TA, Joshi PP, Sokolov K. Preventing protein adsorption and macrophage uptake of gold nanoparticles via a hydrophobic shield. ACS Nano 6(10), 9182-9190 (2012).
39. Villiers C, Freitas H, Couderc R, Villiers MB, Marche P. Analysis of the toxicity of gold nano particles on the immune system: effect on dendritic cell functions. J. Nanopart. Res. 12(1), 55-60 (2010).
40. Wiwanitkit V, Sereemaspun A, Rojanathanes R. Effect of gold nanoparticle on the microscopic morphology of white blood cell. Cytopathology 20(2), 109-110 (2009).
41. See V, Free P, Cesbron Y et al. Cathepsin L digestion of nanobioconjugates upon endocytosis. ACS Nano 3, 2461-2468 (2009).
42. Sharma M, Salisbury RL, Maurer EI, Hussain SM, Sulentic CE. Gold nanoparticles induce transcriptional activity of NF-kappaB in a B-lymphocyte cell line. Nanoscale 5(9), 3747-3756 (2013).
43. Tulinska J, Kazimirova A, Kuricova M et al. Immunotoxicity and genotoxicity testing of PLGA-PEO nanoparticles in human blood cell model. Nanotoxicology doi:10.3109/17435390.2013.816798 (2013) (Epub ahead of print).
44. Jiang H, Liu F, Yang H, Li Y. Effects of cobalt nanoparticles on human T cells in vitro. Biol. Trace Elem. Res. 146(1), 23-29 (2012).
45. Lunov O, Syrovets T, Loos C et al. Amino-functionalized polystyrene nanoparticles activate the NLRP3 infammasome in human macrophages. ACS Nano 5(12), 9648-9657 (2011).
46. 2 nanoparticles in murine dendritic cells. Nanotoxicology 5(3), 326-340 (2011).
47. Guarda G, Dostert C, Staehli F et al. T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 infammasomes. Nature 460(7252), 269-273 (2009).
48. Srivastava R, Burbach BJ, Shimizu Y. NF-kappaB activation in T cells requires discrete control of IkappaB kinase alpha/beta (IKKalpha/beta) phosphorylation and IKKgamma ubiquitination by the ADAP adapter protein. J. Biol. Chem. 285(15), 11100-11105 (2010).
49. Caruso A, Licenziati S, Corulli M et al. Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. Cytometry 27(1), 71-76 (1997).
50. Hosono M, De Boer OJ, Van Der Wal AC et al. Increased expression of T cell activation markers (CD25, CD26, CD40L and CD69) in atherectomy specimens of patients with unstable angina and acute myocardial infarction. Atherosclerosis 168(1), 73-80 (2003).
51. + T cells. Science 286(5443), 1353-1357 (1999).
52. Harrop JA, Reddy M, Dede K et al. Antibodies to TR2 (herpesvirus entry mediator), a new member of the TNF receptor superfamily, block T cell proliferation, expression of activation markers, and production of cytokines. J. Immunol. 161(4), 1786-1794 (1998).
53. + T cells producing Th2-type cytokines. FASEB J. 9(1), 81-86 (1995).
54. Fiorentino DF, Zlotnik A, Vieira P et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 146(10), 3444-3451 (1991).
55. Schoenborn JR, Wilson CB. Regulation of interferon-γ during innate and adaptive immune responses. Adv. Immunol. 96, 41-101 (2007).
56. Westendorp RGJ, Langermans JaM, Huizinga TWJ et al. Genetic infuence on cytokine production and fatal meningococcal disease. Lancet 349(9046), 170-173 (1997).
57. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin. Exp. Immunol. 99(2), 303-310 (1995).
58. Shapira L, Wilensky A, Kinane DF. Effect of genetic variability on the infammatory response to periodontal infection. J. Clin. Periodontol. 32(s6), 72-86 (2005).
59. De Rosa SC, Lu FX, Yu J et al. Vaccination in humans generates broad T cell cytokine responses. J. Immunol. 173(9), 5372-5380 (2004).
60. Connolly NC, Whiteside TL, Wilson C, Kondragunta V, Rinaldo CR, Riddler SA. Therapeutic immunization with human immunodefciency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin. Vaccine Immunol. 15 (2), 284-292 (2008).
61. Lalvani A, Moris P, Voss G et al. Potent induction of focused Th1-type cellular and humoral immune responses by RTS, S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J. Infect. Dis. 180(5), 1656-1664 (1999).
62. Inoue K, Takano H, Yanagisawa R et al. Effects of airway exposure to nanoparticles on lung infammation induced by bacterial endotoxin in mice. Environ. Health Perspect. 114(9), 1325-1330 (2006).
63. Salmen S, Berrueta L. Immune modulators of HIV infection: the role of reactive oxygen species. J. Clin. Cell. Immunol. 3, 121 (2012).
64. Kiessling MK, Linke B, Brechmann M, Suss D, Krammer PH, Gulow K. Inhibition of NF-kappaB induces a switch from CD95L-dependent to CD95L-independent and JNK-mediated apoptosis in T cells. FEBS Lett. 584(22), 4679-4688 (2010).
65. Jones DP. Radical-free biology of oxidative stress. Am. J. Physiol. Cell Physiol. 295(4), C849-C868 (2008).
66. Diebold I, Petry A, Burger M, Hess J, Gorlach A. NOX4 mediates activation of FoxO3a and matrix metalloproteinase-2 expression by urotensin-II. Mol. Biol. Cell 22(22), 4424-4434 (2011).
67. Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat. Rev. Drug Discov. 10(6), 453-471 (2011).